Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Gsk Plc ADR
(NY:
GSK
)
43.50
+0.15 (+0.35%)
Official Closing Price
Updated: 7:00 PM EDT, May 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Gsk Plc ADR
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
31
32
Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
April 13, 2022
Rise and shine, trader! Join me today as we break down all the news behind the biggest pre-market stock movers for Wednesday!
Via
InvestorPlace
Germany Inks COVID-19 Vaccine Deal With CureVac, GSK Until 2029
April 11, 2022
Via
Benzinga
Watch For Continued Gains In Shares Of GlaxoSmithKline PLC (GSK)
April 11, 2022
This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice.
Via
Benzinga
Highly Rated GlaxoSmithKline Eyes Breakout After Racking Up Series Of Wins
April 11, 2022
The move comes after the FDA shut down its Vir-partnered Covid antibody, however.
Via
Investor's Business Daily
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
April 11, 2022
Via
Investor Brand Network
Watch for Continued Gains in Shares of GlaxoSmithKline PLC (GSK)
April 11, 2022
Via
Investor Brand Network
Why Did FDA Pull Authorization For GSK-Vir's COVID-19 Therapy? Read Here
April 06, 2022
Via
Benzinga
CureVac - GSK Start Dosing In Next-Gen COVID-19 Vaccine Candidate Trial
March 30, 2022
Via
Benzinga
What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates?
April 07, 2022
Pharma giant Pfizer, Inc. (NYSE: PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier.
Via
Benzinga
New Large-Scale Observational Study Shows COVID-19 Could Create Vulnerability to Shingles for People Age 50+
April 06, 2022
From
GSK
Via
Business Wire
Good and Bad stock news
April 05, 2022
Microsoft is down because of an FTC investigation of its possible anti-competitive moves.
Via
Talk Markets
EMA Starts Review Of Sanofi-GlaxoSmithKline's COVID-19 Vaccine
March 30, 2022
Via
Benzinga
LifeMine Therapeutics, GSK Ink $70M Drug Discovery, Development Pact
March 23, 2022
Via
Benzinga
Vir Soars As Its Addition To SmallCap 600 Helps Wipe Out Recent Covid Volatility
March 30, 2022
Vir Biotechnology remains under pressure despite its looming addition to a new index.
Via
Investor's Business Daily
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
March 30, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Omicron BA.2 Variant Represents More Than 50% COVID-19 Cases, Says CDC Estimates: WSJ
March 30, 2022
According to the Centers for Disease Control and Prevention estimates, the omicron BA.2 variant represents approximately 55% of new COVID-19 cases in the U.S., as signs suggest infections are edging...
Via
Benzinga
FDA Approves ViiV Healthcare's Cabenuva For Virologically Suppressed Adolescents With HIV
March 29, 2022
Via
Benzinga
Biden Administration Proposes $82B In Spending For Future Pandemics Preparedness
March 29, 2022
President Biden's budget proposal calls for $81.7 billion to spend over five years preparing for future pandemics, which would be a significant investment in boosting the country
Via
Benzinga
Monday Markets News
March 28, 2022
Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.
Via
Talk Markets
FDA Says Current Dose Of GSK-Vir's COVID-19 Therapy Unlikely To Work Against Omicron Subvariant
March 28, 2022
Via
Benzinga
Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs
March 28, 2022
As these Chinese stocks face delisting, some may provide a contrarian play on improving relations between the U.S. and China.
Via
InvestorPlace
Drug makers, Scientists Working For Long COVID Treatments: Reuters
March 25, 2022
Researchers and drugmakers, including those who have launched antiviral pills and monoclonal antibodies for COVID-19, are having early discussions about targeting Long COVID,
Via
Benzinga
How Rivals Merck, Bristol Myers Benefit From Eli Lilly's FDA Snag
March 24, 2022
The Food and Drug Administration on Thursday rejected a lung cancer drug Eli Lilly tested only in China, but LLY stock inched higher.
Via
Investor's Business Daily
Why Most Kids Did Not Suffer Badly Due To COVID-19 Infection? Scientists Look To Solve Mystery: CNBC
March 24, 2022
The COVID-19 pandemic has led to over 6 million fatalities. The scientists are still studying why most children do not suffer badly from coronavirus infection.
Via
Benzinga
Ahead Of Moderna's Midstage mRNA Flu Vaccine Readout, Analyst Says Drugmaker Likely To Be First To Market
March 21, 2022
After COVID-19 vaccine-induced strength, Moderna, Inc. (NASDAQ: MRNA) is on the lookout for the next big catalyst to boost its rangebound stock. The Moderna Analyst: BofA...
Via
Benzinga
Health Experts Forecast Increase In COVID-19 Cases In US Amid New Omicron Subvariant: CNBC
March 21, 2022
U.S. health experts warn that an emerging, highly contagious COVID-19 omicron variant, BA.2, could soon increase domestic coronavirus cases.
Via
Benzinga
WHO Foundation Warns Global Economy To Lose "Trillions Of Dollars" On COVID-19 Vaccine Inequality: CNBC
March 16, 2022
The WHO Foundation CEO, Anil Soni, has told CNBC that the global economy will lose “trillions of dollars” if more COVID-19 vaccines aren&
Via
Benzinga
News-Filled Day
March 15, 2022
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC.
Via
Talk Markets
Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial
March 15, 2022
IDEAYA Biosciences Inc (NASDAQ: IDYA) has announced
Via
Benzinga
GSK/Vir Biotech's COVID-19 Antibody Associated With Resistance Mutations, New Research Shows
March 11, 2022
According to new research in Australia, some people have developed sotrovimab-resistant mutations following infusions with the GlaxoSmithKline Plc (NYSE: GSK...
Via
Benzinga
< Previous
1
2
...
16
17
18
19
20
21
22
23
24
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.